Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
Wednesday, November 16, 2011 - 09:31
in Health & Medicine
Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions.